Patents by Inventor Phillip A. Furman

Phillip A. Furman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified 4?-nucleosides as antiviral agents
    Patent number: 8569478
    Abstract: Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4?-C-substituted ?-D- and ?-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: October 29, 2013
    Assignee: Gilead Pharmasset LLC
    Inventors: Jinfa Du, Phillip Furman, Michael Joseph Sofia
  • MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS
    Publication number: 20110021454
    Abstract: Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4?-C-substituted ?-D- and ?-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided.
    Type: Application
    Filed: September 26, 2006
    Publication date: January 27, 2011
    Applicant: Pharmasset, Inc.
    Inventors: Jinfa Du, Phillip Furman, Michael Joseph Sofia
  • Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses
    Publication number: 20100273740
    Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 28, 2010
    Inventors: Ronald A. FLEMING, Jan V. Hes, Yunsheng Huang, Russ H. Read, Susan L. Morris-Natschke, Khalid S. Ishaq, Louis S. Kucera, Phillip A. Furman
  • Combination Therapy to Treat Hepatitis B Virus
    Publication number: 20090247487
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Application
    Filed: June 12, 2009
    Publication date: October 1, 2009
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
  • Combination therapy to treat hepatitis B virus
    Patent number: 7572800
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: August 11, 2009
    Assignee: Gilead Sciences, Inc.
    Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
  • Methods and compositions for the treatment of respiratory syncytial virus
    Publication number: 20050187191
    Abstract: The invention includes compounds useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.
    Type: Application
    Filed: February 20, 2004
    Publication date: August 25, 2005
    Inventors: Louis Kucera, Susan Morris-Natschke, Khalid Ishaq, Ronald Fleming, Jan Hess, Yunsheng Huang, Russ Read, Phillip Furman
  • Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
    Publication number: 20050187192
    Abstract: Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.
    Type: Application
    Filed: February 20, 2004
    Publication date: August 25, 2005
    Inventors: Ronald Fleming, Jan Hes, Yunsheng Huang, Russ Read, Susan Morris-Natschke, Khalid Ishaq, Louis Kucera, Phillip Furman
  • Combination therapy to treat hepatitis B virus
    Publication number: 20030158150
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 21, 2003
    Applicant: Triangle Pharmaceuticals, Inc.
    Inventors: Phillip A. Furman, George R. Painter, David W. Barry, Franck Rousseau
  • Combination therapy to treat hepatitis B virus
    Patent number: 6528515
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: March 4, 2003
    Assignee: Triangle Pharmaceuticals, Inc.
    Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
  • Use of MKC-442 in combination with other antiviral agents
    Patent number: 6410546
    Abstract: Use of MKC-442 in combination with other antiviral agents for the treatment of patients infected with HIV is disclosed.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: June 25, 2002
    Assignee: Triangle Pharmaceuticals, Inc.
    Inventors: Phillip A. Furman, Cary P. Moxham, David W. Barry, Katyna Borroto-Esoda
  • Use of MKC-442 in combination with other antiviral agents
    Publication number: 20020002166
    Abstract: Use of MKC-442 in combination with other antiviral agents for the treatment of patients infected with HIV is disclosed.
    Type: Application
    Filed: August 14, 2001
    Publication date: January 3, 2002
    Inventors: Phillip A. Furman, Cary P. Moxham, David W. Barry, Katyna Borroto-Esoda
  • Antiviral nucleoside combination
    Patent number: 5234913
    Abstract: Synergistic combinations of nucleoside derivatives, pharmaceutical formulations containing said combinations and use of the combinations in the treatment of retroviral infections are disclosed.
    Type: Grant
    Filed: March 5, 1992
    Date of Patent: August 10, 1993
    Assignee: Burroughs Wellcome Co.
    Inventors: Phillip A. Furman, Jr., George R. Painter, III
  • Treatment of human viral infections
    Patent number: 5093114
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: March 3, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrmaan, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infections
    Patent number: 5086044
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir.
    Type: Grant
    Filed: April 18, 1990
    Date of Patent: February 4, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infections
    Patent number: 4874609
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: October 17, 1989
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infections
    Patent number: 4857511
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: August 15, 1989
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infections
    Patent number: 4847244
    Abstract: Treatments of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: October 20, 1987
    Date of Patent: July 11, 1989
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infections
    Patent number: 4837208
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: October 20, 1987
    Date of Patent: June 6, 1989
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infections
    Patent number: 4833130
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5'-mono, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: October 20, 1987
    Date of Patent: May 23, 1989
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman
  • Treatment of human viral infection
    Patent number: 4828838
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.
    Type: Grant
    Filed: October 21, 1987
    Date of Patent: May 9, 1989
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, David W. Barry, Sandra N. Lehrman, Martha H. St. Clair, Phillip A. Furman